Cargando…

Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening

[Image: see text] Various toxicity and pharmacokinetic evaluations as screening experiments are needed at the drug discovery stage. Currently, to reduce the use of animal experiments and developmental expenses, the development of high-performance predictive models based on quantitative structure–act...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamada, Hideaki, Takahashi, Mari, Ogino, Mizuki, Nomura, Yukihiro, Uesawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568689/
https://www.ncbi.nlm.nih.gov/pubmed/37841172
http://dx.doi.org/10.1021/acsomega.3c04073
_version_ 1785119403220664320
author Mamada, Hideaki
Takahashi, Mari
Ogino, Mizuki
Nomura, Yukihiro
Uesawa, Yoshihiro
author_facet Mamada, Hideaki
Takahashi, Mari
Ogino, Mizuki
Nomura, Yukihiro
Uesawa, Yoshihiro
author_sort Mamada, Hideaki
collection PubMed
description [Image: see text] Various toxicity and pharmacokinetic evaluations as screening experiments are needed at the drug discovery stage. Currently, to reduce the use of animal experiments and developmental expenses, the development of high-performance predictive models based on quantitative structure–activity relationship analysis is desired. From these evaluation targets, we selected 50% lethal dose (LD(50)), blood–brain barrier penetration (BBBP), and the clearance (CL) pathway for this investigation and constructed predictive models for each target using 636–11,886 compounds. First, we constructed predictive models using the DeepSnap-deep learning (DL) method and images of compounds as features. The calculated area under the curve (AUC) and balanced accuracy (BAC) were, respectively, 0.887 and 0.818 for LD(50), 0.893 and 0.824 for BBBP, and 0.883 and 0.763 for the CL pathway. Next, molecular descriptors (MDs) of compounds were calculated using Molecular Operating Environment, alvaDesc, and ADMET Predictor to construct predictive models using the MD-based method. Using these MDs, we constructed predictive models using DataRobot. The calculated AUC and BAC were, respectively, 0.931 and 0.805 for LD(50), 0.919 and 0.849 for BBBP, and 0.900 and 0.807 for the CL pathway. In this investigation, we constructed predictive models combining the DeepSnap-DL and MD-based methods. In ensemble models using the mean predictive probability of the DeepSnap-DL and MD-based methods, the calculated AUC and BAC were, respectively, 0.942 and 0.842 for LD(50), 0.936 and 0.853 for BBBP, and 0.908 and 0.832 for the CL pathway, with improved predictive performance observed for all variables compared with either single method alone. Moreover, in consensus models that adopted only compounds for which the results of the two methods agreed, the calculated BAC for LD(50), BBBP, and the CL pathway were 0.916, 0.918, and 0.847, respectively, indicating higher predictive performance than the ensemble models for all three variables. The predictive models combining the DeepSnap-DL and MD-based methods displayed high predictive performance for LD(50), BBBP, and the CL pathway. Therefore, the application of this approach to prediction targets in various drug discovery screenings is expected to accelerate drug discovery.
format Online
Article
Text
id pubmed-10568689
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-105686892023-10-13 Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening Mamada, Hideaki Takahashi, Mari Ogino, Mizuki Nomura, Yukihiro Uesawa, Yoshihiro ACS Omega [Image: see text] Various toxicity and pharmacokinetic evaluations as screening experiments are needed at the drug discovery stage. Currently, to reduce the use of animal experiments and developmental expenses, the development of high-performance predictive models based on quantitative structure–activity relationship analysis is desired. From these evaluation targets, we selected 50% lethal dose (LD(50)), blood–brain barrier penetration (BBBP), and the clearance (CL) pathway for this investigation and constructed predictive models for each target using 636–11,886 compounds. First, we constructed predictive models using the DeepSnap-deep learning (DL) method and images of compounds as features. The calculated area under the curve (AUC) and balanced accuracy (BAC) were, respectively, 0.887 and 0.818 for LD(50), 0.893 and 0.824 for BBBP, and 0.883 and 0.763 for the CL pathway. Next, molecular descriptors (MDs) of compounds were calculated using Molecular Operating Environment, alvaDesc, and ADMET Predictor to construct predictive models using the MD-based method. Using these MDs, we constructed predictive models using DataRobot. The calculated AUC and BAC were, respectively, 0.931 and 0.805 for LD(50), 0.919 and 0.849 for BBBP, and 0.900 and 0.807 for the CL pathway. In this investigation, we constructed predictive models combining the DeepSnap-DL and MD-based methods. In ensemble models using the mean predictive probability of the DeepSnap-DL and MD-based methods, the calculated AUC and BAC were, respectively, 0.942 and 0.842 for LD(50), 0.936 and 0.853 for BBBP, and 0.908 and 0.832 for the CL pathway, with improved predictive performance observed for all variables compared with either single method alone. Moreover, in consensus models that adopted only compounds for which the results of the two methods agreed, the calculated BAC for LD(50), BBBP, and the CL pathway were 0.916, 0.918, and 0.847, respectively, indicating higher predictive performance than the ensemble models for all three variables. The predictive models combining the DeepSnap-DL and MD-based methods displayed high predictive performance for LD(50), BBBP, and the CL pathway. Therefore, the application of this approach to prediction targets in various drug discovery screenings is expected to accelerate drug discovery. American Chemical Society 2023-09-13 /pmc/articles/PMC10568689/ /pubmed/37841172 http://dx.doi.org/10.1021/acsomega.3c04073 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Mamada, Hideaki
Takahashi, Mari
Ogino, Mizuki
Nomura, Yukihiro
Uesawa, Yoshihiro
Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title_full Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title_fullStr Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title_full_unstemmed Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title_short Predictive Models Based on Molecular Images and Molecular Descriptors for Drug Screening
title_sort predictive models based on molecular images and molecular descriptors for drug screening
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568689/
https://www.ncbi.nlm.nih.gov/pubmed/37841172
http://dx.doi.org/10.1021/acsomega.3c04073
work_keys_str_mv AT mamadahideaki predictivemodelsbasedonmolecularimagesandmoleculardescriptorsfordrugscreening
AT takahashimari predictivemodelsbasedonmolecularimagesandmoleculardescriptorsfordrugscreening
AT oginomizuki predictivemodelsbasedonmolecularimagesandmoleculardescriptorsfordrugscreening
AT nomurayukihiro predictivemodelsbasedonmolecularimagesandmoleculardescriptorsfordrugscreening
AT uesawayoshihiro predictivemodelsbasedonmolecularimagesandmoleculardescriptorsfordrugscreening